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Other names: MTG16; MTGR2; ZMYND4 
Location: 16q24.3 
Local order: telomere; centromeric to CDH15 and 
telomeric to GALNS. 
DNA/RNA 
Description 
CBFA2T3 encodes two alternative transcripts, 
CBFA2T3A and CBFA2T3B, via the use of alternative 
start sites at exons 1A and 1B, respectively. 
CBFA2T3A is 4,265-bp in length, composed of 13 
exons (1A and 2 to 12) spanning approximately 130-kb 
of genomic DNA, and has an ORF of 1,959-bp 
encoding a protein of 653 amino acids. 
CBFA2T3B is 4,034-bp in length, composed of 12 
exons (1B to 12 splicing out exon 3) spanning 
approximately 50-kb of genomic DNA, and has an 
ORF of 1,701-bp encoding a protein of 567 amino 
acids. 
Additional CBFA2T3C and CBFA2T3D isoforms have 
been identified in leukemic and HEL cell lines. 
CBFA2T3C encodes a protein that lacks exons 2 and 3, 
and CBFA2T3D is a truncated protein with out-of-
frame splicing of exon 1A to exon 5. 
The CBFA2T3A open-reading-frame (ORF) may 
include an additional 177 amino acids beyond the 
originally proposed methionine start codon. 
The CBFA2T3B isoform contains a high-density 1-kb 
CpG island within and five prime to the exon 1B start 
site. 
A hypothetical protein FLJ26728 located within and 
proximal to the CpG island transcribes antisense to 
CBFA2T3. Another hypothetical protein FLJ23429 






ETO proteins are composed of four evolutionarily 
conserved domains termed nervy homology regions 
(NHR1 to 4) and three proline-serine-threonine (PST) 
rich regions. The fourth NHR region is also referred to 
as the zinc-finger MYND (zf myeloid-nervy-DEAF-1) 
domain. 
NHR1 shares significant homology to human TATA-
binding protein (TBP)-associated factor 130 (hTAF 
130), hTAF 105, Drosophila accessory or activation 
factor TAF 110, and is often referred to as the TAF 110 
domain. 
NHR2 is a small region containing homo and 
heterodimerization domains and a hydrophobic heptad 
repeat (HHR) unit. 
The sequence of NHR3 is unremarkable in homology 
and often referred to as the nervy domain. 
The C-terminal NHR4 domain exists in numerous 
human, murine, Caenorhabditis elegans and Drosophila 
proteins, and contains a MYND zinc-finger motif. The 
motif is composed of CXXC and two (C-H)XXXC 
regions which correspond to cysteine-histidine 'knuckle 
structures' that are the basic building blocks of many 
zinc-finger proteins. The zinc-finger is common to the 
developmental proteins rat programmed cell death (RP-
8), the human homolog programmed cell death 2 
(PDCD2), deformed epidermal autoregulatory factor-1  
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(DEAF-1), suppressin (SPN), BLU or zinc-finger 
MYND domain containing 10 (ZMYND10), 
adenovirus 5 E1A binding protein (BS69), and CD8 
beta opposite (BOP). 
Expression 
CBFA2T3 is widely expressed in B-cells, blood, brain, 
breast, cervix, colon, eye, kidney tumor, lymph, 
marrow, muscle, pancreas, placenta and tonsil. 
CBFA2T3 exists predominantly as 4.5 and 4.2-kb 
transcripts along with several other minor RNAs in 
heart, brain, placenta, lung, liver, skeletal muscle, 
kidney, pancreas, spleen, thymus, prostate, testis, 
ovary, small intestine, colon and peripheral blood 
leukocyte. 
Localisation 
All ETO members contain nuclear localization signals 
(NLS), some of which may be abrogated through five 
prime variations to enable extracellular targeting. For 
instance, CBFA2T1 has been detected in the cytoplasm 
of Purkinje cells in adult human brain, and both 
CBFA2T1 and CBFA2T3B have been detected in the 
Golgi apparatus, where they may function as cAMP-
dependent protein kinase anchoring proteins. The 
majority of ETO proteins presumably remain in the 
nucleus for transcriptional regulation. 
Function 
CBFA2T3 has been considered to function as a 
transcriptional repressor via interaction with 
corepressor complexes. 
The CBFA2T3A isoform oligomerizes and drags 
MTG8 and MTGR1 to the nucleus, oligomerizes with 
RUNX1-MTG16 fusion proteins in the nucleoplasm, 
interacts with nuclear HDACs 1 and 3, and when 
overexpressed accumulates at the periphery of nucleoli 
in characteristic rings. Because clustered arrays of 
inactive methylated ribosomal DNA (rDNA) repeats 
are also found at the nucleoli periphery, it has been 
speculated that CBFAT23A could be involved in 
methylation silencing of rDNA in the nucleolus. 
The CBFA2T3B isoform has been shown to function in 
T lymphocytes as a kinase anchorage protein, and 
interact with cyclic nucleotide phosphodiesterases, 
suggesting it may function in T cell activation and 
inflammatory response. CBFA2T3B has been shown to 
function as a transcriptional repressor when tetherd to 
a GAL4 DNA-binding domain in gene reporter assays, 
and inhibit the growth of breast tumor cell lines with 
reduced expression when ectopically expressed using 
retrovirus. 
CBFA2T3 has been found to interact with a novel zinc 
finger protein KIA00924 to mediate potent 
transcriptional repression as determined by CAT  
 
 
reporter gene assays. The presence of a zinc-finger 
motif common to developmental proteins suggests that 
CBFA2T3 might function in regulating differentiation 
and morphogenesis. The RP-8 and human homolog 
PDCD2 proteins assume a role in programmed cell 
death, a process essential for epithelial turnover. 
DEAF-1 is essential for early embryonic dorsal 
epidermal, eye and wing development in Drosophila. 
BOP encodes a muscle-restricted protein essential for 
cardiomyocyte differentiation and morphogenesis. 
BLU is a candidate tumor suppressor gene from the 
3p21.3 LOH region in many human cancers, and SPN 
from rat functions as a potent tumor suppressor of 
leukemia, lymphoma and thymoma cells and tumor 
cells from the brain, breast, pituitary and adrenal 
glands. 
CBFA2T3 transcripts of CD34(+) progenitor cells have 
been shown to be rapidly reduced by cytokine-induce 
differentiation into myeloid or erythroid lineages, 
supporting suggestion that CBFA2T3 may function in 
hematopoietic differentiation. The CBFA2T3B CpG 
island contains several Specificity protein 1 (Sp1), 
homeotic, epidermal and insulin growth factor 
recognition sites. High conserved binding sites include 
GATA-1, CREB, F-1 and PKNOX1. 
Homology 
The human gene CBFA2T3 is a member of the eight-
twenty-one (ETO) family of proteins. The human ETO 
family consists of the ETO gene, also known as the 
myeloid translocation gene 8 (MTG8, CBFA2T1), the 
myeloid translocation gene related protein-1 (EHT, 
MTGR1, CBFA2T2), and the myeloid translocation 
gene 16 (MTG16, MTGR2, ZMYND4, HGNC:1537, 
CBFA2T3). 
Murine homologs of the ETO family include mETO 
(cbfa2t1h), ET0-2 (cbfa2t3h), and cbfa2t2h, the latter 
of which is uncharacterised. Chicken cETO and 
Drosophila nervy homologs have also been identified. 
The ETO protein family members and NHRs are highly 
homologous and conserved to each other. The 
CBFA2T3A and B isoforms share significant 
homology to MTG8 (67 and 75%, respectively) and 
MTGR1 (54 and 61%, respectively), and approximately 
30% homology to nervy. CBFA2T3 shares 86% 
homology to the murine ETO-2 (cbfa2t3h), which in 
turn shares 75 and 60% homology to MTG8 and 
MTGR1, respectively, suggesting that ETO-2 is the 
murine homolog of CBFA2T3. MTG8 is approximately 
99, 65 and 30% homologous to murine ETO, MTGR1 
and nervy, respectively. 
Mutations 
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Implicated in 
t(16;21)(q24;q22) in therapy related 
acute myeloid leukemia (t-AML) → 
CBFA2T3/RUNX1 
Note: CBFA2T3 or MTG16 was identified by 
molecular characterization of a second less common 
therapy-related AML translocation involving t(16;21). 
Characterization of the t(16;21) demonstrated that 
RUNX1-MTG16 fusion transcripts similar to RUNX1-
ETO were generated. 
Abnormal Protein 
The RUNX1-MTG8, and to a lesser extent the 
RUNX1-MTG16, fusion transcripts of the 
t(8;21)(q22;q22) and t(16;21) events are most 
recognized for their ability to function as 
transcriptional repressors of genes normally activated 
by RUNX1 through their interaction with corepressor 
complexes involving N-CoR, mSin3A, SMRT, and 
HDACs. 
The MTG8 or CBFA2T1 gene is the most studied 
member of the ETO family and is additionally 
recognized for its ability to function independently as a 
nuclear transcriptional repressor through nuclear 
corepressor complex interaction. Gene targeting 
experiments demonstrating that homozygous mutant 
mice with an inactivating insertion of LacZ in exon 2 of 
the MTG8 locus resulted in massive gastrointestinal 
defects, have also shown that MTG8 and perhaps ETO 
family members are essential for gastrointestinal 
development. 
Multiple NHRs of the ETO family of proteins are 
required and cooperate to mediate transcriptional 
repression. Most of the proteins that interact with 
NHRs have been assigned from studies of RUNX1-
MTG8 and its interacting proteins. Studies originally 
demonstrated that MTG8s NHR2 and NHR4 were 
required for AML-MTG8 to inhibit RUNX1 mediated 
transcriptional activation and initiated the search for 
'corepressor complexes' that bind to these regions. 
Several yeast two-hybrid systems using portions of 
MTG8 as bait demonstrated that specific portions of 
NHR2, NHR3 and NHR4 interact with the human 
nuclear receptor co-repressor (HuN-CoR)-mSin3A-
HDAC1 corepressor complex. 
The N-CoR protein was originally described to interact 
with DNA-bound nuclear receptors to repress 
transcription of target genes through recruitment of 
HDAC containing complexes and was latter shown to 
form complexes with mammalian Sin3 to alter 
chromatin structure and mediate transcriptional 
repression via nuclear receptors and oncoregulatory 
proteins. 
A similar yeast two-hybrid approach also established 
that the corepressor silencing mediator of retinoic acid 
and thyroid hormone receptors (SMRT) interacts with 
MTG8. The zinc-finger NHR4 is necessary but not 
sufficient for repression and interaction with SMRT 
and N-CoR in vitro. The direct physical association of 
MTG8 with corepressors is more complex. A 'core-
repressor domain' containing NHR2 and the 
neighboring amino and carboxy terminal sequences 
was defined and found to be the strongest region of 
interaction with mSin3a and transcriptional repression. 
In the RUNX1-MTG8 translocation product associated 
with myeloid malignancies, the transactivation domain 
of the RUNX1 gene, which normally binds the 
transcriptional coactivators p300-CBP, is replaced by 
almost the entire MTG8 protein. The resultant fusion 
protein recruits a corepressor complex containing 
HDAC activity instead of the coactivators p300 - CBP 
to RUNX1 responsive genes giving rise to leukemia. 
The repression activity of the MTG8 protein was 
demonstrated from a GAL4 DNA binding domain 
(DBD) MTG8 fusion construct which mediated strong 
repression through multimerized GAL4 binding sites 
upstream of a minimal promoter driving a reporter 
gene. Consistent with a mechanism involving MTG8 
and HDAC corepressor interactions, the repressive 
effect of MTG8 was partially overcome with the 
addition of the HDAC inhibitor trichostatin A (TSA). 
Mutational studies of RUNX1-MTG8 have shown that 
NHR4 is responsible for repression of the multidrug 
resistance 1 promoter. 
MTG8 has also been shown to interact with the 
Dentato-rubral and Pallido-luysian atrophy gene 
product, atrophin-1, in a yeast two-hybrid assay. Both 
Dentato-rubral and Pallido-luysian atrophies are 
neurodegenerative disorders caused by expansion of 
polyglutamine tracts. 
Several other transcriptional repressors have been 
shown to interact with MTG8. The promyelocytic 
leukemia zinc-finger (PLZF), a transcriptional 
repressor found in hematopoietic cells and down-
regulated during differentiation of myeloid cell lines 
was shown to exhibit enhanced repressor activity when 
interacting with MTG8 in 293T cells and assayed using 
a reporter plasmid containing four copies of a high 
affinity PLZF binding site linked to firefly luciferase. 
The ability of MTG8 to enhance repression was 
abolished upon addition of HDAC inhibitors TSA and 
sodium butyrate, suggesting that the MTG8 enhanced 
repression by PLZF is also mediated through the 
recruitment of HDACs. 
The Growth factor independence-1 (Gfi-1), a HDAC 
interacting transcriptional repressor found in 
hematopoietic cells, was shown in vitro and in vivo to 
interact with NHR1 and NHR2 of MTG8. These 
interactions together with gene targeting experiments 
demonstrating MTG8s involvement in gastrointestinal 
development, the well established interactions with 
corepressor complexes, and the presence of a zinc-
finger motif common to numerous developmental 
proteins, suggests that ETO family members including 
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CBFA2T3 may play function in regulating cell cycle 
transcription during differentiation and proliferation of 
specific cell type-lineages, for example hematopoietic 
cells as indicated for MTG8. 
Loss of heterozygosity (LOH) of 16q22-
qter in breast cancer, prostate cancer, 
and several other cancers 
Note: This region is frequently deleted in several 
human cancers causing loss of heterozygosity. The 
16q24.3 region including CBFA2T3 spans 
approximately 3-Mb from the marker D16S498 to the 
telomere and contains at least two smallest regions of 
overlap (SROs). These SROs are most frequently 
deleted in early and late stage breast cancer and in 
prostate cancer. Loss of normal function of CBFA2T3 
may be a key event in the early stage of breast cancer. 
LOH on the whole 16q22-qter region is frequently 
detected in breast and prostate cancer. 
CBFA2T3B is a potential tumor suppressor gene 
affected by LOH, aberrant gene expression and 
promoter methylation in breast cancer. Quantitative 
gene expression analysis of 78 genes in the 16q24.3 
region demonstrated that CBFA2T3 was the only gene 
with an aberrant expression profile distinctly similar to 
the known tumor suppressors SYK and CDKN2A. 68 
genes displayed normal expression, six displayed 
mildly aberrant expression (DPEP1, CDH15, 
Hs.17074, Hs.189419, SLC7A5 and AA994450), one 
displayed excessively reduced expression (CA5A), and 
two displayed moderately aberrant expression (CYBA 
and FBX031). The CBFA2T3B promoter region 
displays aberrant hypo and hypermethylation in breast 
tumor cell lines and primary breast tumor samples in 
correlation with aberrant gene expression. 
Disease 
16q22-qter LOH is detected in bilateral breast cancer 
and ductal lavage, in rare inflammatory breast cancer, 
and in several other cancers, including central nervous 
system neuroectodermal and primary ependymomas, 
colorectal liver metastases, gastric tumor, head an
neck squamous cell carcinoma, hepatocellular 
carcinoma, lung tumor, nasopharyngeal tumor, ovarian 
tumor, rhabdomyosarcoma, and Wilms' tumor. 16q22-
qter LOH in ovarian, hepatocellular and particularly 
breast and prostate cancers, exhibit similar SROs, 
suggesting common molecular pathways are affected. 
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